Inactive Instrument

Kolon TissueGene, Inc.

Equities

A950160

KR8840120008

Kolon TissueGene, Inc. announced that it expects to receive $38.79881 billion in funding from Kolon Corporation and another investor

August 11, 2022

Kolon TissueGene, Inc. announced a private placement of 794,000 common shares at a price of $37.327171 per share for gross proceeds of $29.637,774 on August 12, 2022. The transaction will include participation from returning investors, Kolon Corporation for 716,259 common shares and individual investor, Lee Woong-yeol for 77,741 common shares. All securities to be issued must be held for one year.

The transaction has been approved by the board of directors of the company and is expected to close on August 26, 2022.

Latest news about Kolon TissueGene, Inc.

Kolon TissueGene, Inc. announced that it has received $30.000024 million in funding	23-05-14	CI
Kolon TissueGene, Inc. announced that it has received KRW 39.999032395 billion in funding from Kolon Corporation	23-05-09	CI
Kolon TissueGene, Inc. announced that it expects to receive $30.000024 million in funding	23-05-08	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 30 million in funding from Kolon Corporation	22-10-20	CI
Kolon TissueGene, Inc. announced that it has received KRW 33 billion in funding from a group of investors	22-09-06	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 33 billion in funding from a group of investors	22-08-30	CI
Kolon TissueGene, Inc. announced that it has received $29.637774 million in funding from Kolon Corporation	22-08-28	CI
Kolon TissueGene, Inc. announced that it expects to receive $38.79881 billion in funding from Kolon Corporation and another investor	22-08-11	CI
Kolon TissueGene, Inc. Resumes TG-C Phase III Studies in the U.S	21-12-28	CI
Kolon TissueGene, Inc. announced that it has received KRW 29.140887075 billion in funding from Kolon Corporation	21-12-09	CI
Kolon TissueGene, Inc. to Expand Indications for TG-C	21-12-03	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 29.140887075 billion in funding from Kolon Corporation	21-12-01	CI
Kolon TissueGene, Inc. Announces Plans to Resume US Phase III Clinical Trial For TG-C	20-04-13	CI
Kolon TissueGene, Inc.(KOSDAQ:A950160) dropped from S&P Global BMI Index	19-09-23	CI
Kolon TissueGene, Inc. to Start US Phase III Clinical Trial for Invossa™	18-07-06	CI
TissueGene, Inc. has Changed its Name to Kolon TissueGene, Inc	18-03-16	CI
Kolon TissueGene, Inc.(KOSDAQ:A950160) added to S&P Global BMI Index	17-12-18	CI
Kolon TissueGene, Inc. has completed an IPO in the amount of KRW 202.5 billion.	17-11-05	CI
Kolon TissueGene, Inc. has filed an IPO.	17-06-14	CI
TissueGen® Inc. Names Lisa A. Fortier to its Scientific Advisory Board	17-02-27	CI
Kolon TissueGene, Inc. announced that it expects to receive $9.999995 million in funding	16-06-27	CI
TissueGene, Inc. Announces FDA Acceptance Of Invossa™ as Proprietary Name for TissueGene-C	15-06-24	CI
TissueGene, Inc. Appoints Robert A Newman as Chief Operating Officer	15-04-21	CI
TissueGene, Inc. Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of the Knee	14-11-17	CI
TissueGene, Inc. Announces ELUTE(TM) Biodegradable Drug-Loaded Fiber	13-04-09	CI

Chart Kolon TissueGene, Inc.

Duration

Period

More charts

Company Profile

Kolon TissueGene, Inc. is a biopharmaceutical company. The Company develops cell-based therapies to treat osteoarthritis, orthopedic diseases, and other degenerative disorders. The Company's platform technology consists of a combination of allogeneic primary cells combined with genetically modified cells in one injectable therapeutic dose. The Company's lead product candidate is INVOSSA (TG-C), a cell and gene therapy for the treatment of osteoarthritis of the knee that has completed Phase II trials. TG-C is an allogeneic cell and gene therapy involving primary human chondrocytes (cartilage cells), which is delivered via one intra-articular injection into the knee. Its product pipelines fall under the category, such as osteoarthritis, musculoskeletal system disorder and vet medicine. The Company is also developing therapies for musculoskeletal system disorders, such as rheumatoid arthritis, meniscus, and spinal discs.

Sector

More about the company